BIMO guidance agenda
This article was originally published in The Gray Sheet
Executive Summary
FDA's Bioresearch Monitoring program is finalizing 2007 draft guidance on investigators' responsibilities in FDA-regulated clinical trials; updating a 1998 draft on institutional review boards' continuing review after clinical investigation approval to add detail on the criteria, process and frequency of continuing review; and reviewing comments and finalizing a 2006 draft guidance on exceptions from informed consent requirements for emergency research, according to a March 25 1progress report on the Critical Path-originated program. BIMO is also working on a new "guide to informed consent" draft guidance that will discuss topics such as review of patient records, children as subjects and patients' participation in multiple studies
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.